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OBJECTIVES We sought to determine the relationship of delayed hyperenhancement by contrast magnetic
resonance imaging (MRI) to viable and nonviable myocardium within the region at risk
throughout infarct healing.
BACKGROUND The relationship of delayed MRI contrast enhancement patterns to injured but viable
myocardium within the ischemic bed at risk has not been established.
METHODS We compared in vivo and ex vivo MRI contrast enhancement to histopathologic tissue
sections encompassing the entire left ventricle in dogs (n 5 24) subjected to infarction with
(n 5 12) and without (n 5 12) reperfusion at 4 h, 1 day, 3 days, 10 days, 4 weeks and 8 weeks.
In vivo MR imaging was performed 30 min after contrast injection.
RESULTS The sizes and shapes of in vivo myocardial regions of elevated image intensity (828 6 132%
of remote) were the same as those observed ex vivo (241 slices, r 5 0.99, bias 5 0.05 6 1.6%
of left ventricle [LV]). Comparison of ex vivo MRI to triphenyltetrazolim chloride–stained
sections demonstrated that the spatial extent of hyperenhancement was the same as the spatial
extent of infarction at every stage of healing (510 slices, lowest r 5 0.95, largest bias 5 1.7 6
2.9% of LV). Conversely, hyperenhanced regions were smaller than the ischemic bed at risk
defined by fluorescent microparticles at every stage of healing (239 slices, 35 6 24% of risk
region, p , 0.001). Image intensities of viable myocardium within the risk region were the
same as those of remote, normal myocardium (102 6 9% of remote, p 5 NS).
CONCLUSIONS Delayed contrast enhancement by MRI distinguishes between viable and nonviable regions
within the myocardium at risk throughout infarct healing. (J Am Coll Cardiol 2000;36:
1985–91) © 2000 by the American College of Cardiology
During an acute myocardial infarction, myocytes within the
ischemic bed do not all die simultaneously, but rather,
irreversible injury develops as a transmural wavefront occur-
ring first in the subendocardium and then extending toward
the subepicardium (1,2). Clinically, the distinction between
reversible and irreversible injury within the risk region is
important since selecting the appropriate course of action
following an ischemic event depends strongly on whether or
not infarction is already transmural or whether some or all of
the risk region contains viable myocardium in jeopardy of a
future event. This distinction between infarcted myocar-
dium and injured but viable myocardium, however, is often
difficult to make, in part because the severity of the
contractile dysfunction in the infarct zone does not reflect
the transmural extent of necrosis (3).
In a recent study by our group (4), we found a strong
association between irreversible myocardial injury and de-
layed (.5 min) hyperenhancement in magnetic resonance
images (MRI) following administration of Gd-DTPA.
Hyperenhancement occurred in infarcted regions but was
not observed in regions subjected to purely reversible isch-
emic injury (15 min coronary occlusion) despite the pres-
ence of myocardial stunning at the time of the MRI. Other
recent reports, however, suggest a different perspective.
Rogers et al. (5) studied Gd-DTPA enhancement in 17
patients and found that hyperenhanced regions observed
one week after reperfused infarction partially recovered
contractile function by seven weeks. The authors interpreted
this finding as evidence that hyperenhancement can occur in
viable myocardial regions. Pislaru et al. (6) studied an
investigational “necrosis avid” MRI contrast agent,
Gadophrin-2, in a canine model of acute infarction based in
part on the assumption that FDA-approved contrast agents
such as Gd-DTPA do not distinguish between reversible
and irreversible ischemic injury.
While the physiologic interpretation of contrast-
enhanced MRI (ceMRI) remains to be fully elucidated, the
quality of the images continues to improve. Segmented
inversion-recovery MRI pulse sequences now typically result
in hyperenhanced image intensities that are 300% to 500%
greater than nonhyperenhanced regions (4), greatly reduc-
ing observer subjectivity regarding the shape and transmural
extent of hyperenhanced regions. In patients with ischemic
heart disease, cine MRI is easily combined with contrast
MRI to examine regional wall motion and contrast en-
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hancement with perfect registration in multiple short and
long axis views. Considering the wide availability of MRI
scanners and the routine use of Gd-DTPA and similar
agents for noncardiac clinical indications (5,7,8), these
recent improvements in image quality underscore the im-
portance of establishing the relationship of delayed myocar-
dial hyperenhancement to the underlying pathophysiology.
In the present study, we evaluated ceMRI of postischemic
myocardium following administration of Gd-DTPA at
different times throughout infarct healing. Dogs were sub-
jected to either transient 90-min or permanent coronary
artery occlusion, imaged in vivo by MRI, and sacrificed at
either 4 h, 1 day, 3 days, 10 days, 4 weeks or 8 weeks. All
hearts were imaged ex vivo at 500 3 500 3 500-mm spatial
resolution and then sectioned into registered contiguous
2-mm-thick tissue slices encompassing the entire left ven-
tricle (LV). Regions of MRI hyperenhancement were com-
pared to regions at risk of infarction defined by fluorescent
microparticles, to infarcted regions defined by triphenyltet-
razolium chloride (TTC) staining and to histology by light
microscopy.
METHODS
Experimental preparation. Twenty-eight 25- to 30-kg
mongrel dogs were studied. The care and treatment of all
animals was in accordance with the Position of the Amer-
ican Heart Association on Research Animal Use, adopted
November 15, 1984. Under sterile technique, a lateral
thoracotomy was performed, the pericardium was opened,
and the proximal left anterior descending or left circumflex
artery was carefully dissected and occluded to produce an
infarction. In one group of animals (n 5 12), the artery was
permanently occluded with a snare ligature; in another
group (n 5 16), the artery was occluded for 90 min with a
removable soft occluder, and then reperfusion was restored.
In animals to be studied at one day and beyond, the chest
was then sutured closed, and the animals were allowed to
recover.
MRI and experimental protocol. Animals were studied at
4 h, 1 day, 3 days, 10 days, 4 weeks and 8 weeks.
In vivo imaging. In vivo images were acquired for all time
points except 4 h (due to scanner scheduling limitations).
Animals were anesthetized, intubated, transported to the
MRI facility and imaged in the right lateral decubitus
position (1.5T Siemens Symphony; Erlangen, Germany).
Approximately 30 min after 0.3 mmol/kg Gd-DTPA i.v.,
contiguous 5-mm-thick short-axis T1-weighted images
were acquired from base to apex (ca. 15 per heart) using a
segmented inversion-recovery pulse sequence described in
detail elsewhere (9). Animals were then sacrificed and the
hearts removed for further study. In the animals with
reperfused infarcts, the coronary artery was reoccluded
before sacrifice and 120 ml of 1.3% fluorescent micropar-
ticles (1 to 10 mm in diameter; Duke Scientific Corporation;
Palo Alto, California) was injected into the left atrium to
identify the myocardium at risk of infarction (10–12).
To test whether or not the observed enhancement pat-
terns were specific to the use of Gd-DTPA, eight animals
were imaged on consecutive days using Gd-HP-DO3A on
the first day and Gd-DTPA on the next day. Gd-HP-
DO3A (ProHance; Bracco Diagnostics, Inc.; Milan, Italy)
is another clinically approved contrast agent that has a
molecular weight (ca. 800 daltons), T1 relaxivity (ca. 4
mmol21 s21), and biologic distribution (extracellular) sim-
ilar to Gd-DTPA. Two animals were studied at each of four
time points (3 days, 10 days, 4 weeks and 8 weeks).
Ex vivo imaging. After excision, hearts were quickly im-
mersed in cold (4°C) saline solution, rinsed, and ventricular
cavities were blotted dry. Balloons containing 99.9% deu-
terated water (D2O) were placed in the ventricular cavities
and three fiduciary markers defining the short axis of the
heart were glued to the epicardium near the base. The hearts
were then suspended vertically in a standard knee coil and
three-dimensional gradient-echo images (TR 5 20 ms,
TE 5 3.2 ms) were acquired with a spatial resolution of
500 3 500 3 500 mm. T1-weighting was achieved by the
use of a large flip angle (70°).
Histochemical staining. Following ex vivo imaging, hearts
were cooled and made partially stiff by short, repeated
immersions in 95% ethanol precooled to 280°C and then
sectioned into 2-mm-thick short axis slices from base to
apex (ca. 25 per heart) using a commercial rotating meat
slicer along the plane defined by the three epicardial
markers. All slices were stained with 2% TTC and photo-
graphed under room light to determine infarct size and
under ultraviolet light to determine the myocardium at risk.
Light microscopy. In 24 animals, one transmural block of
tissue was obtained from the infarct territory and a second
transmural block was obtained from a normal region oppo-
site the infarct territory. Each tissue block was photo-
graphed under room light (for TTC) and ultraviolet light
(for fluorescent microparticles) and then stained with he-
matoxylin and eosin (H&E) and Masson’s trichrome.
Data analysis. IN VIVO HYPERENHANCEMENT. Image in-
tensities were measured in hyperenhanced and remote,
nonhyperenhanced regions of myocardium using a software
package (NIH Image, National Institute of Health, Be-
thesda, Maryland). Hyperenhancement was defined as an
image intensity .3 SDs above the mean of remote myo-
cardium. The spatial extent of hyperenhancement was
expressed as a percentage of the LV on a slice-by-slice basis.
Consistent with previous analyses (4,13), the measurement
Abbreviations and Acronyms
ceMRI 5 contrast-enhanced magnetic resonance
imaging
LOA 5 limits of agreement
LV 5 left ventricle
MRI 5 magnetic resonance imaging
ROI 5 region of interest
TTC 5 triphenyltetrazolium chloride
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of the spatial extent of hyperenhancement included suben-
docardial regions of hypoenhancement within the core of
the hyperenhanced region if these regions were present.
IN VIVO VERSUS EX VIVO HYPERENHANCEMENT. For each
animal, the ex vivo images were registered to the in vivo
images for blinded comparison of hyperenhancement pat-
terns. First, the short-axis slice locations acquired in vivo
were displayed on an in vivo long-axis image (Fig. 2). Next,
each high resolution ex vivo data set was loaded into a
multiplanar reconstruction tool (MPR; Siemens Medical
Systems; Erlangen, Germany) and contiguous 5-mm-thick
short-axis ex vivo images were extracted from the three
dimensional data set according to the slice positions dis-
played in the in vivo long-axis image. A separate observer
measured hyperenhanced regions in the same manner used
for the in vivo images.
EX VIVO HYPERENHANCEMENT VERSUS INFARCT SIZE AND
REGIONS AT RISK. Each three-dimensional ex vivo MRI
dataset was also rotated to the short-axis orientation defined
by the three epicardial markers and images were extracted at
the same slice locations as the histologic slices. An observer
blinded to the MRI results measured infarct size using the
TTC-stained slices and another observer blinded to the
TTC results analyzed the MRIs for the spatial extent of
hyperenhancement. The risk regions were analyzed in a
similar manner based on photographs taken under ultravi-
olet light. In all cases, regions were expressed as a percentage
of the LV on a slice-by-slice basis. Regions-of-interest
(ROI) were also drawn on the ex vivo MRIs to determine
the image intensities corresponding to the following: 1)
infarcted myocardium (TTC negative); 2) at risk but not
infarcted myocardium (fluorescent negative and TTC pos-
itive); and 3) normal myocardium (fluorescent positive and
TTC positive) remote from the infarction site. The ROIs
were placed only on those MRIs in which the corresponding
histologic slices clearly demonstrated the presence of all
three regions within the same short-axis slice.
LIGHT MICROSCOPY. Pairs of H&E- and trichrome-
stained tissue sections were presented to a pathologist
(J.W.L.) blinded to the results of the MRI, TTC and
fluorescent microparticle examinations. The pathologist ex-
amined each section for the presence or absence of irrevers-
ible injury and, if present, outlined regions without viable
myocytes by hand on the glass slides. Irreversible injury was
defined using standard histologic criteria such as coagula-
tion and contraction band necrosis acutely and collagen
replacement chronically. Based on these outlines, the per-
cent surface area of each irreversibly injured region was
calculated for later comparison to TTC-negative regions
and to regions without fluorescent microparticles based on
photographs of the same tissue blocks taken before H&E
and trichrome staining (see “Experimental Protocol”).
Statistical analysis. All results were expressed as mean 6
SD. The method of Bland and Altman (14) was used to
compare in vivo versus ex vivo hyperenhancement, hyper-
enhancement with infarct size and hyperenhancement with
the region at risk. Image intensities amongst regions were
compared using repeated measures analysis of variance with
Bonferronni correction. All tests were two tailed and p ,
0.05 was considered significant.
RESULTS
In vivo and ex vivo contrast enhancement. Hyperen-
hancement was observed in vivo at 1 day, 3 days, 10 days, 4
weeks and 8 weeks in both nonreperfused and reperfused
infarcts (Fig. 1). Image intensities in hyperenhanced regions
were 828 6 132% of remote, normal myocardium. Suben-
docardial hypoenhanced regions within the central core of
the hyperenhanced region were observed in 12 of the 24
animals 30 min postcontrast. These hypoenhanced regions
were most prominent for nonreperfused infarcts; however,
they were also present in large reperfused infarcts.
The sizes and shapes of in vivo hyperenhanced regions
were similar to those observed ex vivo (Fig. 2). The
correlation between the spatial extent of in vivo versus ex
vivo hyperenhancement was high for all injuries studied
Figure 1. Hyperenhancement was observed at 1 day, 3 days, 10 days, 4 weeks and 8 weeks after nonreperfused (top row) and reperfused (bottom row)
myocardial infarction.
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(241 slices, lowest r 5 0.99), the mean difference in area was
nearly zero (largest bias 5 0.70% of LV area) and the limits
of agreement (LOA) were narrow (largest LOA 5 63.1%
of LV area).
Hyperenhancement versus infarct size. Figure 3 com-
pares ex vivo ceMRI to corresponding TTC-stained sec-
tions. The location and spatial extent of ceMRI hyperen-
hancement appeared to be the same as the infarct zone
delineated by TTC. Linear regression analysis revealed a
high correlation coefficient (510 slices, lowest r 5 0.95).
Bland-Altman analysis showed a high degree of agreement
between MRI and TTC at every stage of infarct healing
regardless of reperfusion status (largest bias 5 1.7% of LV
area; maximum LOA 5 bias 6 5.7% of LV area). Similarly,
when total infarct size by TTC (mean, 8.0 6 1.6% of LV;
range, 0.5 to 29.2) was compared to the spatial extent of in
vivo hyperenhancement (8.2 6 1.5%; range, 1.0 to 30.5), a
correlation coefficient of 0.96 was found and Bland-Altman
analysis showed a high degree of agreement (bias: 0.24% of
LV; limits of agreement of 18.0 and 27.6% of LV).
Hyperenhancement versus regions at risk. Areas of hy-
perenhancement were smaller than areas at risk (Fig. 4,
35 6 24% of the risk region, largest bias 5 17.9% of LV
area), and the LOA were wide (maximum LOA 5 bias 6
16.7% of LV area).
ceMRI within the risk region. Figure 5 compares hyper-
enhanced, infarcted and risk regions of an animal with a
reperfused acute infarction. The risk region (area without
fluorescence) was significantly larger than the infarct (TTC
negative). The MRI demonstrates that viable myocardium
within the risk region (“at risk but not infarcted”) did not
hyperenhance. Light microscopy confirmed that myocytes
in the “at risk but not infarcted” region (region 2 of Fig. 5)
were viable. Figure 6 compares ceMRI image intensities
Figure 2. Hyperenhancement observed in vivo was similar to that observed ex vivo.
Figure 3. The size and shape of hyperenhanced regions by MRI closely matched those of irreversible injury defined by TTC throughout infarct healing.
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within the risk region to remote, normal myocardium.
Within the risk region, image intensities were elevated in
nonviable regions (243 6 54% of remote, p , 0.001) but
not in viable regions (102 6 9% of remote, p 5 NS) for
every stage of infarct healing.
Light microscopy. Of the 55 pairs of H&E- and
trichrome-stained slides, the pathologist identified regions
of irreversible injury in 33 of 33 paired slides from sections
with TTC-negative regions and 0 of 22 paired slides from
sections without TTC-negative regions. The percent sur-
face areas of regions without viable myocytes identified by
the pathologist by light microscopy were similar to the
percent surface areas of TTC-negative regions (r 5 0.99,
bias 5 1.19% of total tissue area) but were significantly
smaller than the percent surface areas of regions without
fluorescent microparticles (bias 5 16.14%). Within irrevers-
ibly injured regions, the pathologist identified the full range
of histologic features characteristic of infarcts at various
stages of healing, including coagulation and contraction
band necrosis (Fig. 5, arrows), neutrophils and macrophages
in infarcts 4 h to three days old, granulation tissue in
10-day-old and four-week-old infarcts and mature collage-
nous scar at eight weeks.
Gd-HP-DO3A versus Gd-DTPA. For the eight animals
in which in vivo ceMRI was performed using both contrast
agents, no differences were detected in the spatial extent of
hyperenhancement (92 slices, bias 5 0.4 6 3.2% of LV
area, p 5 NS).
DISCUSSION
The main findings of this study were as follows: 1) the
spatial extent of in vivo and ex vivo hyperenhancement was
identical when the same slice thickness was used (5 mm); 2)
the spatial extent of ex vivo hyperenhancement at high
resolution (0.5 3 0.5 3 0.5 mm) was the same as infarct size
defined by TTC; and 3) within the risk region, viable
myocardium was distinguished from nonviable myocardium
as nonhyperenhanced and hyperenhanced regions, respec-
tively. These findings held throughout infarct healing and
irrespective of reperfusion status.
Comparison to previous studies. Several previous studies
by our group (13,15) and others (16–22) have compared
contrast enhancement to infarct size using “thick” histologic
sections cut by hand and typically not precisely oriented in
the same plane as the images. In a recent report by our
group (4), we developed a method by which high resolution
ex vivo images could be accurately registered with “thin”
(2 mm) histologic sections. The purpose of the current study
was to apply this method to address three key issues raised
but not addressed by our recent report (4) or by previous
studies (16–22). First, we systematically compared in vivo to
ex vivo enhancement to determine if the data comparing ex
vivo images to histology can be used as a basis for the
interpretation of in vivo images. Second, we used fluores-
cent microparticles to determine whether hyperenhance-
ment occurs in viable regions at risk of infarction that
surround infarcted regions. Third, we studied hyperen-
hancement throughout infarct healing because it remained
unclear whether or not hyperenhancement would be ob-
served at all stages of infarct healing and how hyperen-
hancement, if present, would relate to the profound cellular-
Figure 4. The size and shape of regions with reduced perfusion (“at risk”) were larger than the hyperenhanced areas by ceMRI.
Figure 5. Comparison of MRI hyperenhancement (left upper panel),
TTC staining (left middle panel) and the myocardium at risk (region
without fluorescent microparticles, left lower panel) in an animal with a
1-day-old reperfused infarction. Light microscopy views of region 1 (not at
risk, not infarcted), region 2 (at risk but not infarcted) and region 3
(infarcted) are shown on the right panels. Arrows point to contraction
bands. See text for details.
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level changes that occur during the transition from acutely
necrotic myocytes to collagenous scar. Study of these issues
with a level of detail significantly beyond that of previous
studies was motivated by observations of clearly defined,
nontransmural regions of hyperenhancement in patients
with coronary artery disease (4,9).
Timing of in vivo imaging. All images were acquired
approximately 30 min postcontrast for two reasons. First, in
earlier studies (8,13,15), we found that “delayed” hyperen-
hancement is established by approximately 5 min postcon-
trast. Second, we have empirically observed that the endo-
cardial border is often more easily detected at later times
because the image intensity of the blood pool decreases at a
faster rate than that of hyperenhanced myocardial regions.
The data of the current study do not address the time course
of first-pass contrast enhancement or the time course of
contrast penetration in regions of microvascular damage
(13,15).
Contrast enhancement of the risk region. We found that
the myocardial region at risk is characterized by two
different enhancement patterns: hyperenhanced and nonhy-
perenhanced. Hyperenhancement appeared in a subregion
within the risk region and was exclusively associated with
nonviable myocardium. Regions without hyperenhance-
ment but within the risk region were found to contain viable
myocytes both by TTC staining and light microscopy. The
association of hyperenhancement to nonviable myocardium
was observed throughout infarct healing and was unaffected
by reperfusion status.
To our knowledge, our data are the first in which contrast
enhancement within the risk region has been studied
beyond 24 h postinfarct. One of the few studies to address
this issue within the first 24 h is that of Schaefer et al. (16)
who, unlike our current findings, reported that hyperen-
hancement overestimated infarct size. It should be noted,
however, that the animals in the study by Schaefer et al. (16)
received the MRI contrast agent during reactive hyperemia,
suggesting that hyperenhancement may have occurred in
hyperemic regions without infarction as well as in infarcted
regions. In a smaller group of animals reported in the same
article, Schaefer et al. (16) found that when the contrast
agent was administered 90 min after reperfusion, the hy-
peremic response was no longer present and the spatial
extent of hyperenhancement was much smaller (8.6 vs.
25.9% of LV) despite similar regions at risk and infarct
sizes.
Contrast enhancement of the infarct zone. In agreement
with previous findings, our data show hyperenhancement of
acute infarcts 4 h to 3 days old both with (15–18,21,22) and
without (19,20,23,24) reperfusion. For older infarcts, the
data of some previous studies indicate that hyperenhance-
ment is observed (8,22,25) whereas others do not (26,27). In
the present study, we found that hyperenhancement persists
at 10 days, 4 weeks and 8 weeks. Discrepant findings
regarding whether or not older infarcts hyperenhance may
relate to both the process of infarct healing and the MRI
technique employed. Myocardial infarcts may shrink by as
much as 400% during infarct healing (28) making older
infarcts inherently more difficult to detect. In addition, pulse
sequences with a more limited ability to distinguish differ-
ences in postcontrast longitudinal relaxation times (T1) may
reduce an observer’s ability to detect infarcted regions (9).
In a previous study of two-day-old reperfused infarcts
(13), we found that the spatial extent of in vivo hyperen-
hancement was 12% larger than infarcted regions. The
method of our current study was developed specifically to
improve our ability to examine this issue. In vivo spatial
resolution was approximately eightfold higher (1.2 3 3.3 3
10 mm/1 3 1 3 5 mm ’ 8) and the number of histologic
slices per animal was 25 compared to 5 in our previous study
(13). Perhaps more importantly, the intermediate stage of ex
vivo imaging greatly improved our ability to register indi-
Figure 6. Hyperenhancement was not observed in “at risk but not infarcted” regions.
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vidual slices. When examined at this level of detail, the data
indicate that the spatial extent of hyperenhancement is
identical to infarct size. It is important to note that the
spatial extent of hyperenhancement may appear slightly
larger than infarct size when spatial resolution is not
adequate to portray the three-dimensional shape of the
infarct (4) (partial volume effect).
Subendocardial regions of hypoenhancement within
larger regions of hyperenhancement were detected in 12 of
the 24 animals. Impeded contrast penetration may relate to
microvascular occlusion (13,18,29) in reperfused and non-
reperfused infarcts and/or a closed infarct-related artery in
the nonreperfused group.
In summary, when spatial resolution is adequate, regions
“at risk but not infarcted” do not hyperenhance and hyper-
enhancement is identical to infarct size throughout infarct
healing. We conclude that delayed contrast enhancement by
MRI distinguishes between viable and nonviable regions
within the myocardium at risk.
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